Brivaracetam Film-coated tablet + Brivaracetam oral solution
Phase 3Recruiting 0 watching 0 views this week๐ Rising
74
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Absence Epilepsy
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Trial Timeline
Jul 10, 2024 โ Mar 1, 2030
NCT ID
NCT06315322About Brivaracetam Film-coated tablet + Brivaracetam oral solution
Brivaracetam Film-coated tablet + Brivaracetam oral solution is a phase 3 stage product being developed by UCB for Childhood Absence Epilepsy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06315322. Target conditions include Childhood Absence Epilepsy, Juvenile Absence Epilepsy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06315322 | Phase 3 | Recruiting |
| NCT05109234 | Phase 3 | Completed |
Competing Products
20 competing products in Childhood Absence Epilepsy